Co-Diagnostics Inc (CODX) FinancialsCODXCo-Diagnostics Inc

Evaluating the bottom line, Co-Diagnostics Inc maintains a gross margin of -48.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3732.47%, while the net margin is -3782.43%. These profitability ratios, combined with a Return on Equity (ROE) of -178.00%, provide a clear picture of how effectively CODX converts its operational activities into shareholder value.

In the context of the broader market, CODX competes directly with industry leaders such as VIVS and CLDI. With a market capitalization of $2.16M, it holds a significant position in the sector. When comparing efficiency, CODX's gross margin of -48.76% stands against VIVS's 100.00% and CLDI's N/A. Such benchmarking helps identify whether Co-Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Co-Diagnostics reported a Q2 2026 revenue of $166,131, a slight increase from the previous year, but the company continues to post significant net losses, with a net loss of $6.3 million in Q2 2026. The gross margin remains negative at -48.76%, indicating ongoing operational challenges.